When there aren’t any clinical investigations of cannabis for the treatment of diabetes mellitus in scientific research, there are a few preclinical studies that indicate the cannabinoids found in marijuana may provide symptomatic relief to those afflicted by diabetes mellitus. Medical marijuana is also known to transform the development of this disease according to a 2006 study published within the journal auto immunity.
The research reported that the 5 mg injections of the non psychoactive online cbd merchant account cannabinoid CBD every day significantly reduced the incidence of diabetes in mice and researchers reported that while around 86% of untreated control mice at the study developed diabetes, by contrast just 30% of mice which were treated using CBD improved the disorder. Diabetes Mellitus refers to a set of auto immune diseases which are characterized by defects in the secretion of insulin by the pancreas. This leads to hyperglycemia or an excessively substantial concentration of sugar in the bloodvessels.
While type 1 diabetes sufferers must count upon insulin therapy for survival, sufferers of diabetes produce insufficient amounts of insulin and also their affliction might typically be controlled with diet. In actuality, statistics suggest that after heart disease and cancer, diabetes mellitus will be the next significant cause of death in the United States. It can also lead to nerve damage, kidney failure, blindness, hardening of the blood vessels, and eventually death.
Researchers at the Medical College of Virginia reported at the March 2006 issue of the American Journal of Pathology that CBD treated rats experienced significant protection from parasitic retinopathy if these were treated for extended periods of 1 to 30 days. Diabetic retinopathy, the main cause of blindness in adults is characterized by a break down of this blood-retinal barrier and bronchial oxygen deprivation.
Medical marijuana is well known to alleviate neuropathic pain related to diabetes mellitus and studies published in the journal Neuroscience Letters in 2004 reported that mice that were administered a receptor agonist for cannabis undergone a drop in diabetes related tactile allodynia or pain caused by a non-injurious epidermis stimulus in comparison with the non treated controllers. These findings imply that the cannabinoids at MMJ might have great therapeutic potential to take care of experimental neuropathic pain caused with diabetes mellitus.